Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Operating Expenses: 2009-2025

Historic Operating Expenses for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to $168.7 million.

  • Cytokinetics' Operating Expenses rose 19.42% to $168.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $660.1 million, marking a year-over-year increase of 25.06%. This contributed to the annual value of $554.7 million for FY2024, which is 10.12% up from last year.
  • As of Q3 2025, Cytokinetics' Operating Expenses stood at $168.7 million, which was down 5.38% from $178.3 million recorded in Q2 2025.
  • Cytokinetics' Operating Expenses' 5-year high stood at $178.3 million during Q2 2025, with a 5-year trough of $47.2 million in Q1 2021.
  • For the 3-year period, Cytokinetics' Operating Expenses averaged around $142.1 million, with its median value being $130.4 million (2024).
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 104.47% in 2021, then fell by 1.56% in 2024.
  • Cytokinetics' Operating Expenses (Quarterly) stood at $77.3 million in 2021, then soared by 66.86% to $129.0 million in 2022, then increased by 0.08% to $129.1 million in 2023, then climbed by 20.82% to $156.0 million in 2024, then grew by 19.42% to $168.7 million in 2025.
  • Its Operating Expenses was $168.7 million in Q3 2025, compared to $178.3 million in Q2 2025 and $157.2 million in Q1 2025.